Aurinia Pharmaceuticals Inc (NAS:AUPH)
$ 5.36 -0.06 (-1.11%) Market Cap: 766.58 Mil Enterprise Value: 543.79 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 72/100

Aurinia Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2022 / 02:45PM GMT
Release Date Price: $18.75 (+1.96%)
Mallika Prasad

Good morning, and thank you for joining us today. My name is Mallika, and I'm an associate in JPMorgan's Healthcare Group. (Operator Instructions)

With that, I'm pleased to introduce you to Peter Greenleaf, CEO of Aurinia Pharmaceuticals. I know that he is very excited to tell you about his story, so we'll turn it over to Peter.

Peter S. Greenleaf
Aurinia Pharmaceuticals Inc. - President, CEO & Director

Good morning, Mallika, and good morning, everyone. Thanks for joining the call, and thank you to everyone at JPMorgan for having us as part of the conference today. Well, I know it's late in the game, we're Thursday, and this all kind of kicked off on Monday or over the weekend. So I know as investors, you've been I'm sure, going through many presentations and individual one-on-ones. Two things before we get started off here.

One is just logistically, I'm not sharing my screen. So there is a slide deck associated with the presentation. So what I'll try to do is, as I move from a slide is at least call out where I am within the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot